# APBA Kısa Özet

A 12-week, double-blind, quasi-randomized, placebo-controlled clinical trial evaluated the efficacy and safety of Coleus forskohlii extract, marketed as Forcslim, on body weight loss in 60 overweight adults aged 20–70 years. Participants were assigned to receive either Forcslim or a placebo, and researchers tracked changes in body weight, body mass index, body composition, waist circumference, lipid profile, and a range of safety markers. Compared with the placebo group, the Forcslim group showed significant reductions in body weight and waist circumference, including a mean reduction of –1.83 cm in waist circumference (p = 0.001). Improvements in lipid profile parameters were also observed. No clinically significant changes were reported in metabolic markers, liver or muscle enzyme levels, heart rate, blood pressure, or adverse effects, supporting a favorable safety profile. The authors concluded that C. forskohlii extract supplementation may serve as a safe and effective alternative to synthetic anti-obesity drugs.

# Çalışma neyi araştırdı?

Overweight and obesity have become global health challenges, and safe, well-tolerated weight management options are needed. Many synthetic anti-obesity drugs carry side effects or are not suitable for long-term use, prompting interest in botanical extracts with traditional and emerging scientific support. Coleus forskohlii is a plant whose root extract has been investigated for potential effects on body weight and body composition. This study specifically tested whether a standardized extract called Forcslim could produce meaningful weight loss and improve anthropometric and metabolic outcomes in overweight individuals without compromising safety.

The primary research aim was to evaluate the efficacy of Forcslim supplementation on body weight loss over 12 weeks. Secondary aims included assessing changes in body mass index, body composition, waist circumference, lipid profile, and safety indicators such as metabolic, hepatic, and cardiovascular markers. The study also sought to determine whether Forcslim could be positioned as a natural alternative to synthetic weight-loss medications in clinical practice.

# Yöntem

This was a quasi-randomized, double-blind, placebo-controlled clinical trial conducted over 12 weeks. The study included 60 overweight subjects aged 20–70 years. Eligible participants were assigned to receive either Forcslim or a placebo, and group allocation was concealed from participants to maintain blinding.

Key efficacy outcome measures included:

  • Body weight
  • Body mass index (BMI)
  • Body composition
  • Anthropometric parameters, including waist circumference
  • Lipid profile parameters

Safety was assessed using:

  • Metabolic markers
  • Liver enzyme levels
  • Muscle enzyme levels
  • Heart rate
  • Blood pressure
  • Reported adverse effects

The quasi-randomization method was not fully described in the available record, which introduces some potential selection bias. However, the double-blind design and placebo control provide a reasonable framework for comparing the intervention group with the control group. All outcome measurements were collected across the 12-week study period, allowing researchers to track changes over time.

# Temel bulgular

The study reported several statistically significant differences between the Forcslim group and the placebo group:

  • Body weight: The Forcslim group demonstrated significant reductions in body weight compared with the placebo group.
  • Waist circumference: A statistically significant reduction of –1.83 cm was observed in the Forcslim group (p = 0.001).
  • Lipid profile: Forcslim was associated with improvements in lipid profile parameters compared with placebo.
  • Safety markers: No clinically significant changes were observed in metabolic markers, liver enzyme levels, muscle enzyme levels, heart rate, or blood pressure.
  • Adverse effects: No clinically significant adverse effects were reported during the study.

These findings indicate that Forcslim supplementation had measurable effects on central adiposity and overall body weight while maintaining a tolerability profile similar to placebo. The lack of meaningful changes in hepatic, muscular, metabolic, or cardiovascular safety indicators supports the short-term safety of the extract.

# Bulgular ne anlama geliyor?

The results suggest that Coleus forskohlii extract (Forcslim) can produce meaningful reductions in body weight and waist circumference in overweight adults over a 12-week period. The reduction in waist circumference is particularly relevant because central adiposity is a known risk factor for cardiometabolic conditions. Improvements in lipid profile add further evidence that Forcslim may have metabolic benefits beyond simple weight reduction.

The absence of clinically significant changes in safety markers suggests that Forcslim was well tolerated in this population. This is important for a dietary supplement intended for weight management, as tolerability and safety are key considerations for individuals who may need to use the product for extended periods. However, because this was a relatively short trial with a small sample size, the findings should be interpreted as preliminary evidence rather than conclusive proof of long-term efficacy.

The study authors concluded that C. forskohlii extract may serve as a safe and effective alternative to synthetic anti-obesity drugs. This conclusion is cautiously supported by the data, but it should be considered in light of the study's limitations, including the quasi-randomized design and the absence of long-term follow-up.

# Klinik önem

The findings have practical implications for clinicians and individuals seeking natural weight-management strategies. For overweight adults who are unable or unwilling to use pharmaceutical anti-obesity agents, a standardized Coleus forskohlii extract may offer a well-tolerated adjunct to diet and exercise. The observed reductions in body weight and waist circumference, combined with a favorable safety profile, suggest that Forcslim could be considered as a dietary supplement to support weight loss goals.

That said, clinicians should interpret these results within the context of the trial's limitations. The study enrolled only 60 participants, all of whom were overweight adults aged 20–70 years, so the findings may not generalize to other populations, such as older adults, normal-weight individuals, or people with severe obesity or obesity-related comorbidities. The 12-week duration limits conclusions about long-term safety and sustainability of weight loss. Additionally, the quasi-randomization method could have introduced selection bias, and it is not clear whether study personnel beyond those handling participant allocation were blinded.

Nevertheless, the absence of clinically significant adverse effects is reassuring and supports further investigation of C. forskohlii as a natural option for weight management. Future research with larger samples, longer durations, and more rigorous randomization protocols is needed to confirm these findings and clarify the role of Forcslim in clinical practice.

# Sınırlılıklar

  • Quasi-randomization: The randomization method was not fully described, which may introduce selection bias and reduces confidence in the comparability of groups at baseline.
  • Population generalizability: The study included only overweight individuals aged 20–70 years; results may not apply to other age groups, normal-weight individuals, or those with severe obesity.
  • Short duration: The 12-week intervention limits the ability to assess long-term efficacy, persistence of weight loss, or delayed adverse effects.
  • Blinding limitations: While participants were blinded, it is unclear whether all study personnel were blinded beyond the participant allocation stage.
  • Precision: The study is described as having imprecise estimates, and the small sample size increases the risk of random error.
  • External validity concerns: Citation-based attention metrics do not establish clinical validity or evidence quality, and no formal conflict-of-interest statement was available in the provided record.

These limitations do not negate the positive findings, but they should guide how the results are applied in clinical decision-making until further confirmatory research is available.